HRPK20040528B3 - Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure - Google Patents

Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Info

Publication number
HRPK20040528B3
HRPK20040528B3 HR20040528A HRP20040528A HRPK20040528B3 HR PK20040528 B3 HRPK20040528 B3 HR PK20040528B3 HR 20040528 A HR20040528 A HR 20040528A HR P20040528 A HRP20040528 A HR P20040528A HR PK20040528 B3 HRPK20040528 B3 HR PK20040528B3
Authority
HR
Croatia
Prior art keywords
treatment
reuptake inhibitors
norepinephrine reuptake
cognitive failure
cognitive
Prior art date
Application number
HR20040528A
Other languages
English (en)
Croatian (hr)
Inventor
Porter Bymaster Franklin
Richard Gehlert Donald
Lee Mckinzie David
Renkin Yang Charles
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20040528A2 publication Critical patent/HRP20040528A2/hr
Publication of HRPK20040528B3 publication Critical patent/HRPK20040528B3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HR20040528A 2001-12-11 2004-06-09 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure HRPK20040528B3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (2)

Publication Number Publication Date
HRP20040528A2 HRP20040528A2 (en) 2004-10-31
HRPK20040528B3 true HRPK20040528B3 (en) 2006-03-31

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040528A HRPK20040528B3 (en) 2001-12-11 2004-06-09 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Country Status (26)

Country Link
US (1) US20050009925A1 (xx)
EP (1) EP1458368B1 (xx)
JP (1) JP2005517647A (xx)
KR (1) KR20040066895A (xx)
CN (1) CN1713900A (xx)
AU (1) AU2002352625A1 (xx)
BR (1) BR0213581A (xx)
CA (1) CA2467802A1 (xx)
CO (1) CO5590907A2 (xx)
CZ (1) CZ2004709A3 (xx)
DE (1) DE60223718T2 (xx)
EA (1) EA200400793A1 (xx)
EC (1) ECSP045145A (xx)
ES (1) ES2295435T3 (xx)
HR (1) HRPK20040528B3 (xx)
HU (1) HUP0402619A3 (xx)
IL (1) IL161989A0 (xx)
MX (1) MXPA04005716A (xx)
MY (1) MY136367A (xx)
NO (1) NO20042904L (xx)
NZ (1) NZ532065A (xx)
PL (1) PL369311A1 (xx)
SK (1) SK2442004A3 (xx)
TW (1) TW200300672A (xx)
WO (1) WO2003049724A1 (xx)
ZA (1) ZA200404274B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
GEP20043160B (en) * 1999-10-13 2004-01-26 Pfizer Products Inc Us Biaryl Ether Derivatives, Pharmaceutical Compositions Containing Them and Their Use as Monoamine Reuptake Inhibitors
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Also Published As

Publication number Publication date
CZ2004709A3 (cs) 2004-10-13
PL369311A1 (en) 2005-04-18
DE60223718T2 (de) 2008-10-30
CN1713900A (zh) 2005-12-28
EP1458368A1 (en) 2004-09-22
MXPA04005716A (es) 2004-12-06
DE60223718D1 (de) 2008-01-03
ECSP045145A (es) 2004-07-23
WO2003049724A1 (en) 2003-06-19
NZ532065A (en) 2007-03-30
SK2442004A3 (en) 2004-12-01
ES2295435T3 (es) 2008-04-16
US20050009925A1 (en) 2005-01-13
JP2005517647A (ja) 2005-06-16
HRP20040528A2 (en) 2004-10-31
KR20040066895A (ko) 2004-07-27
CO5590907A2 (es) 2005-12-30
IL161989A0 (en) 2005-11-20
AU2002352625A1 (en) 2003-06-23
EP1458368B1 (en) 2007-11-21
EA200400793A1 (ru) 2004-10-28
HUP0402619A2 (hu) 2005-03-29
ZA200404274B (en) 2005-09-13
HUP0402619A3 (en) 2008-04-28
TW200300672A (en) 2003-06-16
NO20042904L (no) 2004-09-07
MY136367A (en) 2008-09-30
CA2467802A1 (en) 2003-06-19
BR0213581A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
NZ502853A (en) Treatment of conduct disorder with a norepinephrine reuptake inhibitor such as tomoxetine
HRPK20040528B3 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
HRP20030910B1 (en) Tartarate salts 5,8,14-triazatetracyclo {10.3.1.02,11.04,9}-hexadeca-2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereof
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
YU69902A (sh) Novi derivati piperazina
TW200518758A (en) HIV replication inhibiting purine derivatives
HRP20100614T1 (en) 3,7-diamino-10h-phenothiazine salts and their use
RS52625B (en) FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
NO20063572L (no) Kinazolinditosylatsalt forbindelser
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP045193A (es) "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"
HRP20120323T1 (en) Diarylhydantoin compounds
CO5280078A1 (es) Compuestos
CY1107852T1 (el) Νεες χρησεις αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη της ημικρανιας
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
BR0112252A (pt) Derivados de pirazole
BR0115936A (pt) 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
PL378555A1 (pl) Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK
SE0202429D0 (sv) Novel Compounds
UY28360A1 (es) Nuevos compuestos
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
DK1791537T3 (da) 3-arylthioindol-2-carboxamidderivater og analoger deraf som inhibitorer af casein-kinase
RS52427B (en) ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20061017

Year of fee payment: 5

PBKO Lapse due to non-payment of renewal fee for consensual patent

Effective date: 20071118